INSULIN THERAPY DURING PERITONEAL-DIALYSI S

Major fluctuations of blood sugar, hyperinsulinemia and the formation of insulinemia and the formation of antibodies can be prevented by int raperitoneal insulin administration in patients with diabetic nephropa thy during peritoneal dialysis. In instillation of insulin into the em pty abdominal cavity, the reductions in insulin requirement are most p ronounced compared to subcutaneous administration. If insulin is admin istered into the abdominal cavity along with the dialyzing solution, o n the one hand there are losses of activity owing to delayed absorptio n to the plastic surface of the dialyzing solution bag and systems. Th ese may be so pronounced that intraperitoneal insulin administration i s uneconomic. The effectiveness of peritoneal dialysis is not affected by intraperitoneal administration increases slightly only in CAPD, bu t not in intermittent dialysis.